An estimated 1 million people get shingles each year, with about 1 in 10 developing postherpetic neuralgia that lasts months or years, and 1% – 4% being hospitalized for complications. Despite the availability of a shingles vaccine, about only 1 in 3 eligible adults ≥ 60 years old and just 37% of adults ≥ 65 years old have been vaccinated. Clinicians should recognize the risk factors for shingles (e.g., increasing age, decline in cell-mediated immunity, gender, race, chronic disease, etc.) and take proactive measures in promoting vaccination. Primary care settings are ideal for identifying appropriate patients for shingles vaccination, as well as discussing shingles and shingles vaccination. However, barriers to implementing a shingles protocol may exist.
The first episode of this CMEOCast podcast series focuses on reinforcing the importance of vaccination against shingles, improving vaccination uptake in ethnic minorities and at-risk patients, and developing best practices to implement a shingles protocol in primary care settings.
At the end of this CME/CE activity, participants should be able to develop best practices to implement a shingles protocol in primary care settings.
The following learning objectives pertain only to those requesting CNE or CPE credit: Describe best practices for a shingles protocol in primary care settings.
This educational activity is supported by an educational grant from GlaxoSmithKline.
Physicians, PAs, nurse practitioners, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Schaffner has no disclosures to report.
Dr. Gorfinkel reports that she receives research support from GlaxoSmithKline and Merck & Co., Inc. She is on the advisory committee and a consultant for GlaxoSmithKline.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-132-H06-P.
Call us at 877.CME.PROS (877.263.7767).